X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA FRESENIUS KABI ONCO. NATCO PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 33.8 22.1 153.0% View Chart
P/BV x 17.2 3.1 553.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 NATCO PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
FRESENIUS KABI ONCO.
Mar-13
NATCO PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs877176 498.3%   
Low Rs42479 539.5%   
Sales per share (Unadj.) Rs223.437.7 592.9%  
Earnings per share (Unadj.) Rs31.15.1 610.0%  
Cash flow per share (Unadj.) Rs40.36.7 599.0%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.542.5 515.9%  
Shares outstanding (eoy) m33.07158.23 20.9%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.4 86.2%   
Avg P/E ratio x20.925.0 83.8%  
P/CF ratio (eoy) x16.118.9 85.3%  
Price / Book Value ratio x3.03.0 99.0%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,50420,135 106.8%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m1,128703 160.4%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m7,3895,963 123.9%  
Other income Rs m16718 928.3%   
Total revenues Rs m7,5565,981 126.3%   
Gross profit Rs m1,7931,430 125.4%  
Depreciation Rs m304258 118.0%   
Interest Rs m366-26 -1,408.5%   
Profit before tax Rs m1,2901,216 106.1%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m309342 90.2%   
Profit after tax Rs m1,027806 127.5%  
Gross profit margin %24.324.0 101.2%  
Effective tax rate %23.928.1 85.1%   
Net profit margin %13.913.5 102.9%  
BALANCE SHEET DATA
Current assets Rs m3,6815,102 72.2%   
Current liabilities Rs m3,1232,385 130.9%   
Net working cap to sales %7.645.6 16.6%  
Current ratio x1.22.1 55.1%  
Inventory Days Days89150 59.6%  
Debtors Days Days59113 51.8%  
Net fixed assets Rs m7,6855,148 149.3%   
Share capital Rs m331158 209.0%   
"Free" reserves Rs m6,6706,556 101.7%   
Net worth Rs m7,2596,732 107.8%   
Long term debt Rs m955952 100.3%   
Total assets Rs m11,95710,388 115.1%  
Interest coverage x4.5-45.8 -9.9%   
Debt to equity ratio x0.10.1 93.0%  
Sales to assets ratio x0.60.6 107.7%   
Return on assets %11.77.5 155.2%  
Return on equity %14.212.0 118.2%  
Return on capital %20.714.6 141.9%  
Exports to sales %39.474.5 52.8%   
Imports to sales %5.724.8 23.0%   
Exports (fob) Rs m2,9084,441 65.5%   
Imports (cif) Rs m4211,477 28.5%   
Fx inflow Rs m3,4455,298 65.0%   
Fx outflow Rs m7031,772 39.7%   
Net fx Rs m2,7433,525 77.8%   
CASH FLOW
From Operations Rs m1,4401,274 113.0%  
From Investments Rs m-1,089-1,204 90.5%  
From Financial Activity Rs m-353-196 179.9%  
Net Cashflow Rs m-1-126 1.2%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 81.0 1.8%  
Indian inst/Mut Fund % 7.8 0.3 2,613.3%  
FIIs % 16.6 9.6 173.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 9.1 285.7%  
Shareholders   25,395 42,599 59.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - PIRAMAL ENTERPRISES COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS